Another potential blow to the development of new treatments for Alzheimer’s disease with a US FDA expert advisory committee voting that trial data does not provide enough evidence to demonstrate the efficacy of Biogen's aducanumab.
A blow for Alzheimer’s with committee voting against potential treatment
November 9, 2020 Latest News
Latest Video
New Stories
-
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
Vitrafy takes its frozen platelet push to America's Midwest
September 30, 2026 - - Australian Biotech -
Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback
September 30, 2026 - - Australian Biotech -
FDA fast tracks Telix scan that could spare men prostate biopsies
September 30, 2026 - - Australian Biotech -
Australian broadcast personality reveals the scars shingles left behind
September 30, 2026 - - Latest News
